Cardiotonic drugs constitute a pharmaceutical class aimed at augmenting the contractile strength of the heart muscle and enhancing its pumping efficiency. This category of medications plays a pivotal role in addressing diverse cardiovascular conditions, particularly heart failure. Their mechanism involves bolstering the vigor of each cardiac contraction, ultimately improving cardiac output and ensuring efficient blood circulation throughout the body. Notable examples of cardiotonic drugs include milrinone and dobutamine, which work by influencing specific pathways to enhance myocardial contractility. The application of cardiotonic drugs is meticulously monitored due to their narrow therapeutic window and the potential for adverse effects. In contemporary medical practice, these medications are often integrated into comprehensive treatment plans, frequently alongside other cardiovascular drugs, to optimize therapeutic outcomes for individuals with various heart-related disorders.
Title : New recommendations for the prevention of sudden cardiac death in athletes and recreational sports
Sekib Sokolovic, ASA Hospital Sarajevo, Bosnia and Herzegowina
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation
Title : An adult case of polysplenia syndrome associated with sinus node dysfunction
Apoorva Tripathi, Oxford University Hospitals, United Kingdom
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : A unique cell-driven phenomenon in the heart and the promising future of the innovative translational tools to manage cardiac self-renewal and regeneration
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Young hearts at risk: Hidden cardiovascular damage and the role of social determinants of health among youth with type 1 diabetes in Kenya
Phoebe Wamalwa, Ministry of Health, Kenya